# US 10,245,313 B2 · DNA motif compounds and methods for inducing specific antibodies and cellular immunity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,245,313 B2
- Document ID: US10245313B2
- Status: Granted
- Kind: B2
- Application number: 14/921,323
- Filed: 2015-10-23
- Published: 2016-04-28
- Granted: 2019-04-02
- Earliest claimed: 2014-10-24
- Assignees: Versitech Limited; Nanjing University
- Applicants: Versitech Limited; Center for Public Health Research, Nanjing University
- Inventors: Zhiwei Chen; Xilin Wu; Zhiwei Wu
- Web page: https://patentgrep.com/patent/US10245313B2

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/12: Viral antigens
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/575: {humoral response}
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to the field of applied immunotechnology and medicine. More specifically, it relates to DNA motif vaccine design, glyco-DNA motif vaccine design, and immunogen design for producing antibodies against an epitope of arbitrary sequences or polysaccharide epitope, particularly those epitopes against which it is otherwise very difficult to induce antibodies, such as those of HIV-1. The present invention also relates to immunogen design to induce robust cellular and humoral immunity.

## Claims

### Claim 1

An immunogenic composition comprising:
a mixture of different plasmids, each of which encodes a motif peptide comprising the sequence xxxxxNCSFNITTxxxx (SEQ ID NO: 1), wherein x stands for any amino acid residue, and wherein the x residues flanking NCSFNITT motif are different when compared to another plasmid in the mixture.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein the motif peptide is modified to add host-derived carbohydrates on an amino acid residue of Asparagine (N).

### Claim 3 (depends on 1)

The immunogenic composition of claim 1, further comprising a sequence consisting of SEQ ID NO: 13.

### Claim 4 (depends on 1)

The immunogenic composition of claim 1, wherein the plasmids are PD1-p24 plasmids with a pVAX backbone.

### Claim 5 (depends on 1)

A method of inducing an immune response in a patient comprising administering the immunogenic composition of claim 1.

### Claim 6 (depends on 1)

A kit comprising a therapeutically effective amount of the immunogenic composition of claim 1.

### Claim 7 (depends on 6)

The kit of claim 6, further comprising a sequence consisting of SEQ ID NO: 13.

### Claim 8 (depends on 1)

The immunogenic composition of claim 1, further comprising one or more primers selected from the group consisting of SEQ ID NO: 14, 15, 16, 17, 18, and 19.

### Claim 9 (depends on 6)

The kit of claim 6, wherein the kit further comprises one or more primers selected from the group consisting of SEQ ID NO: 14, 15, 16, 17, 18, and 19.